Sign in

You're signed outSign in or to get full access.

Ernest Scheidemann

Chief Financial Officer at Aspire Biopharma Holdings
Executive

About Ernest Scheidemann

Ernest J. Scheidemann is the Chief Financial Officer and Principal Financial and Accounting Officer of Aspire Biopharma Holdings, Inc. . He was appointed CFO of Aspire Biopharma, Inc. in July 2022 and is a Certified Public Accountant (CPA) . As of the company’s September 2025 prospectus, he is 64 years old . His annual bonus eligibility is tied to achieved company performance metrics for revenue, profitability, and the development of new business relationships, as determined by the board, providing pay-for-performance alignment .

Past Roles

OrganizationRoleYearsStrategic Impact
Benchmark Builders, Inc.Chief Financial OfficerApr 2017 – Nov 2018Led finance for a construction firm through operational and financial management transition
ASG Technologies, Inc.Chief Financial Officer2008 – 2015CFO of global software company later acquired by Rocket Software, indicating large-scale finance leadership and exit preparedness
WCI CommunitiesTreasurer and Chief Financial Officer2004 – 2008Oversaw finance for a ~$2.0B publicly traded homebuilder during cyclical market conditions
AT&T CorpProgressive finance and accounting leadership roles1984 – 1999Built foundational corporate finance and accounting expertise at a major telecom

External Roles

OrganizationRoleYearsStrategic Impact
FinTrust Consulting, LLCAdvisor/outsourced CFO/financial advisor to public/private companies, special situations, and start-upsNov 2018 – presentProvides broad advisory reach; exposure to capital markets and operational finance across varied mandates

Fixed Compensation

ItemFY/EffectiveAmount/Structure
Annual Base Salary (CFO)Employment Agreement (post-Business Combination)$240,000
Consulting Arrangement Compensation2024$150,000 (independent consulting arrangement)
Bonus EligibilityOngoingAnnual performance-based bonus tied to revenue, profitability, and new business relationships; targets determined by the board (target % not disclosed)

Performance Compensation

MetricWeightingTargetActualPayoutVesting
RevenueNot disclosedNot disclosedNot disclosedNot disclosedNot disclosed
ProfitabilityNot disclosedNot disclosedNot disclosedNot disclosedNot disclosed
Development of new business relationshipsNot disclosedNot disclosedNot disclosedNot disclosedNot disclosed

Notes:

  • The 2024 Omnibus Incentive Plan subjects awards to clawback policies and applicable laws imposing mandatory recoupment .
  • Reverse Stock Split mechanics provide proportionate adjustments to RSAs/RSUs, options, and warrants, maintaining value and exercise economics post-split .

Equity Ownership & Alignment

ItemValue
Total beneficial ownership564,168 shares
Ownership as % of shares outstanding1.1%
Ownership vehicleShares held by Turkey Bay Holdings LLC, beneficially owned by Mr. Scheidemann
Vested vs unvested sharesNot disclosed
Options (exercisable vs unexercisable)Not disclosed; outstanding awards and convertibles subject to proportional adjustment in reverse split
Shares pledged as collateralNot disclosed
Insider trading policyBlackout periods; all insider trades must be pre-cleared with legal counsel
Clawback policyCompany-level clawback policy referenced; Plan awards subject to mandatory repayment per policy/law

Employment Terms

  • Appointment and Tenure: Appointed CFO in July 2022; currently serves as CFO and Principal Financial and Accounting Officer .
  • Term and Salary Review: Employment agreement has an indefinite term; annual base salary of $240,000, subject to annual review .
  • Bonus Structure: Eligible for annual performance-based bonuses tied to revenue, profitability, and development of new business relationships; goals set by the board .
  • Severance: If terminated without “cause” or resigns for “good reason,” severance consists of (i) earned but unpaid base salary, (ii) incurred but unreimbursed documented reasonable business expenses, and (iii) any other amounts due under applicable law; subject to release and covenant compliance (no salary/bonus multiples or accelerated vesting disclosed) .
  • Restrictive Covenants: Non-disparagement, confidentiality, invention assignment, non-interference, and employee/customer non-solicitation .
  • Non-Compete: Form of Non-Compete referenced (Exhibit 10.10 to 8-K filed Feb 21, 2025) .
  • Clawback: Company clawback policy referenced (Exhibit 99.7); Plan awards subject to clawback/recoupment .
  • Insider Trading: Blackout periods and trade pre-clearance required .

Governance and Certifications

  • CFO Certifications: Signed SOX 302 and SOX 906 certifications for Q3 2025, affirming disclosure controls, fair presentation, and internal control disclosures .
  • Codes and Charters: Code of Ethics, audit committee charter, and compensation committee charter filed; clawback policy referenced .

Investment Implications

  • Alignment: Meaningful personal stake (1.1%) via Turkey Bay Holdings LLC supports alignment, though not a controlling position .
  • Pay-for-Performance: Bonus structure explicitly tied to revenue, profitability, and business development suggests incentive alignment; lack of disclosed weights/targets limits transparency .
  • Risk Controls: Blackout/pre-clearance trading policy and clawback coverage reduce governance and misconduct risk; reverse split mechanics avoid unintended windfalls on equity-linked awards .
  • Retention/Exit Economics: Severance limited to accrued obligations with no disclosed change-of-control multiples or accelerated vesting, implying low golden parachute risk but limited retention protections versus market norms .
  • Execution Profile: Deep CFO track record across software (ASG), homebuilding (WCI), construction (Benchmark), and large-cap telecom (AT&T), plus advisory breadth via FinTrust, supports competency; however, absent disclosed performance outcomes (TSR/revenue/EBITDA) during tenure constrains quantitative assessment .